Drug Patents owned by Genzyme

1. Drug name - MOZOBIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7897590 GENZYME Methods to mobilize progenitor/stem cells Jul, 2023

(9 months from now)

US6987102 GENZYME Methods to mobilize progenitor/stem cells Jul, 2023

(9 months from now)

Drugs and Companies using PLERIXAFOR ingredient

Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with non-hodgkin's lymphoma & multiple myeloma

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
24MG/1.2ML (20MG/ML) SOLUTION;SUBCUTANEOUS Prescription

2. Drug name - RENVELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095509 GENZYME Sachet formulation for amine polymers Dec, 2030

(8 years from now)

Drugs and Companies using SEVELAMER CARBONATE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
2.4GM/PACKET FOR SUSPENSION;ORAL Prescription
800MG/PACKET FOR SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.